Background: Heparin is commonly given during hemodialysis (HD). Patients undergoing HD have a high rate of gastrointestinal bleeding (GIB). It is unclear whether or when it is safe to give heparin after acute GIB. We describe the patterns and safety of heparin use with outpatient HD following an acute GIB. Methods: We identified patients aged ≥67 who, from 2004-2008, experienced GIB requiring hospitalization within 2 days of receiving maintenance HD with heparin. We used Cox regression to estimate the risk of recurrent GIB and death associated with receiving heparin the day they resumed outpatient HD post-GIB. Results: Of the 1,342 patients who had GIB, 1,158 (86%) received heparin at a median dose of 4,000 units with their first outpatient HD session after discharge from GIB. On average, their post-GIB doses were slightly lower than their pre-GIB doses (mean change: -214 ± 3,266 units, p < 0.02). However, only 27% of patients had a decrease in their dose, while 21% had their dose increased. We did not find an increased risk of death or recurrent GIB associated with using heparin post-GIB (HR; 95% confidence interval (CI), for death: 1.01; 0.69-1.48; for recurrent GIB: 0.78; 0.39-1.57). Conclusions: The vast majority of these high-risk patients received heparin on the very first day they resumed outpatient HD post-GIB, and the majority at unchanged doses to those received pre-GIB. Even if the practice was not associated with increased risks of death or re-bleeding, it highlights an area for possible system-based improvement to the care for patients on HD.

Keywords:
Anti-coagulation, Gastrointestinal bleeding, Hemodialysis , Heparin
1.
Shen JI, Winkelmayer WC: Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis 2012;60:473-486.
2.
Yang JY, Lee TC, Montez-Rath ME, et al: Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 2012;23:495-506.
3.
Holden RM, Harman GJ, Wang M, Holland D, Day AG: Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:105-110.
4.
Chan KE, Lazarus JM, Thadhani R, Hakim RM: Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-2233.
5.
Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK: Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-2668.
6.
Wizemann V, Tong L, Satayathum S, et al: Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-1106.
7.
Davenport A: What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol 2011;7:499-508.
8.
Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, Baker DW: Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. JAMA 2007;297:831-841.
9.
Bates DW, Gawande AA: Improving safety with information technology. N Engl J Med 2003;348:2526-2534.
10.
Rural Urban Commuting Area Codes Data. 2012. http://depts.washington.edu/uwruca/ruca-data.php (5 January 2012, date last accessed).
11.
Census Bureau Regions and Divisions with State FIPS Codes. 2012. http://www.census.gov/geo/www/reg_div.txt (5 January 2012, date last accessed).
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.